San Francisco, November 6, 2023 – Recardio Inc., a late stage clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases, is participating in the BIO-EUROPE Conference 2023 in Munich.
Read MorePhase 3 Heal-MI Study Published
San Francisco, July 5, 2023 – Recardio Inc., a late stage clinical stage life science company developing therapies for cardiovascular and other diseases, announced that its global pivotal Phase 3 HEAL-MI trial was published at clinicaltrials.gov.
Read MoreClosings of Series C Financing Round
San Francisco, May 31, 2023 – Recardio Inc., a late stage clinical stage life science company developing therapies for cardiovascular and other diseases, announced closings of its Series C financing round.
Read MoreRecardio at BIO International Convention 2023
San Francisco, May 2, 2023 – Recardio Inc., a clinical-stage life science company focusing on regenerative therapies for cardiovascular and other diseases, announced today that it is participating in the BIO International Convention 2023 in Boston.
Read MoreRecardio at J.P. Morgan Conference 2023
San Francisco, January 9, 2023 – Recardio Inc., a late-stage clinical-stage life science company focusing on therapies for cardiovascular diseases, is attending the annual J.P. Morgan Healthcare Week in San Francisco.
Read More